Abstract：
Immunotherapy for cancer treatment has gained increased attention in recent years. Recently, our group reported the case of a patient with glioblastoma who underwent vaccination based on dendritic cells and experienced a strong Th1 immune response together with near-complete tumor remission. Here we report the results of a phase I/II prospective, non-controlled clinical trial with 37 patients harboring glioblastoma or grade 4 astrocytomas. At the time of first recurrence after surgery, patients began receiving monthly intradermal injections of allogenic DC-autologous tumor cell hybridomas. Overall survival, quality of life, and immunological profiles were assessed prospectively. Compared with patients in the Genomic Data Commons data bank, overall survival for vaccinated patients with glioblastoma was 27.6 ± 2.4 months (vs. 16.3 ± 0.7, log-rank p < 0.001, hazard ratio 0.53, 95%CI 0.36-0.78, p < 0.01), and it was 59.5 ± 15.9 for vaccinated astrocytoma grade 4 patients (vs. 19.8 ± 2.5, log-rank p < 0.05, hazard ratio 0.18, 95%CI 0.05-0.62, p < 0.01). Furthermore, seven vaccinated patients (two IDH-1-mutated and five wild type) remain alive at the time of this report (overall survival 47.9 months, SD 21.1, range: 25.4-78.6 months since diagnosis; and 34.2 months since recurrence, range: 17.8 to 40.7, SD 21.3). We believe that the data reported here can foster the improvement of treatment protocols for high-grade gliomas based on cellular immunotherapy.
摘要：
近年来，用于癌症治疗的免疫疗法获得了越来越多的关注。最近,我们研究小组报告了一例胶质母细胞瘤患者,该患者接受了基于树突状细胞的疫苗接种,并经历了强烈的Th1免疫应答,同时肿瘤几乎完全缓解.在这里，我们报告了I/II期前瞻性的结果，非对照临床试验37例患者有胶质母细胞瘤或4级星形细胞瘤。手术后第一次复发时，患者开始接受每月皮内注射同种异体DC-自体肿瘤细胞杂交瘤.总生存率,生活质量,和免疫学特征进行了前瞻性评估。与基因组数据共享数据库中的患者相比，接种疫苗的胶质母细胞瘤患者的总生存期为27.6±2.4个月(vs.16.3±0.7，对数秩p<0.001，危险比0.53，95CI0.36-0.78，p<0.01），接种疫苗的星形细胞瘤4级患者为59.5±15.9(vs.19.8±2.5，对数秩p<0.05，风险比0.18，95CI0.05-0.62，p<0.01）。此外，7名接种疫苗的患者（2名IDH-1突变和5名野生型）在本报告时仍然存活（总生存期47.9个月，SD21.1，范围：诊断后25.4-78.6个月；复发后34.2个月，范围：17.8至40.7，SD21.3）。我们认为，本文报道的数据可以促进基于细胞免疫疗法的高级别神经胶质瘤治疗方案的改进。
